Mesterolone Tablets
Mesterolone Tablets British Dragon — Overview
Mesterolone Tablets deliver mesterolone at 25 mg per tablet — the compound marketed for decades as Proviron. Among all oral androgens used in performance protocols, mesterolone occupies a structurally unique position: it is a 1α-methyl dihydrotestosterone derivative that is not 17α-alkylated. Every other practical oral AAS — stanozolol, oxandrolone, methandienone, fluoxymesterone — carries the 17α-methyl modification that enables oral bioavailability at the cost of hepatic stress. Mesterolone achieves oral activity through a different structural pathway, which means it does not impose the liver enzyme elevation that is universally associated with oral AAS. This is its defining characteristic and the primary reason it can be run for longer periods and alongside other hepatotoxic orals without compounding liver load.
The trade-off is that mesterolone's anabolic activity in muscle tissue is weak — the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD) rapidly inactivates it in muscle. Its meaningful pharmacological actions are SHBG binding, mild aromatase inhibition, and direct androgenic stimulation in tissues where 3α-HSD activity is lower. This profile makes it a support and adjunct compound — not a mass builder, but a tool for increasing free testosterone bioavailability, managing estrogen-related symptoms, and maintaining androgen tone and libido. steroidwarehouse.com stocks Mesterolone Tablets as part of British Dragon's oral lineup.
About the Compound
Mesterolone is synthesized from dihydrotestosterone by the addition of a 1α-methyl group. This modification slows hepatic metabolism enough to produce meaningful oral bioavailability without requiring the 17α-alkylation that burdens the liver. The resulting compound retains DHT's key pharmacological properties — strong androgen receptor binding, no aromatization, no conversion to estrogenic metabolites — while adding a structural feature that makes sustained oral administration practical.
The 1α-methyl group also partially protects mesterolone from 3α-HSD inactivation in the liver, allowing adequate blood levels after oral dosing. However, in skeletal muscle, 3α-HSD activity is sufficient to inactivate mesterolone before it produces significant anabolic effect. This is why the compound's anabolic-to-androgenic ratio is heavily skewed toward androgenic: it is a strong androgen in tissues with low 3α-HSD activity (prostate, skin, CNS) but weak in muscle.
Plasma half-life is approximately 12 hours, requiring twice-daily or three-times-daily dosing to maintain stable blood levels. The compound binds sex hormone-binding globulin with high affinity — a key property that displaces bound testosterone, increasing the free testosterone fraction available for androgen receptor activation without changing total testosterone dose. At 50–75 mg/day, this SHBG displacement effect is clinically measurable and practically relevant in stacks where maximizing free testosterone bioavailability from a given testosterone dose is the goal.
What Mesterolone Does
Mesterolone produces its effects through three overlapping mechanisms, each operating in different contexts:
- SHBG displacement and free testosterone elevation — the most practically important effect in performance use. Mesterolone's high SHBG binding affinity competes with testosterone for binding sites, displacing bound testosterone into the free fraction. Since only free (unbound) testosterone is biologically active at the androgen receptor, this displacement amplifies the effective androgenic output of a given testosterone dose without adding more testosterone. At 50–75 mg/day added to a testosterone-based cycle, this effect translates to measurably higher free testosterone levels.
- Mild aromatase inhibition — mesterolone exhibits weak competitive inhibition of the aromatase enzyme. At standard doses (25–100 mg/day), this inhibition is substantially weaker than dedicated aromatase inhibitors such as anastrozole. It is sufficient to contribute to a drier, lower-estrogen environment but cannot substitute for a genuine AI on cycles with significant aromatase substrate load. Where mesterolone's anti-estrogen contribution is most useful is in lower-testosterone protocols or cruise phases where full AI intervention would overcorrect E2.
- Androgenic stimulation — libido, mood, drive — in CNS and reproductive tissues, mesterolone acts as a direct androgen. This produces reliable improvements in libido, sexual function, and androgenic drive — effects that are particularly useful when testosterone is suppressed (during PCT), when TRT doses are sub-optimal, or when aromatase inhibitor use has reduced estradiol to a level where libido suffers despite adequate total testosterone.
What mesterolone does not do: it does not build muscle mass at any practical dose. Users expecting anabolic gains from mesterolone will see none — the 3α-HSD inactivation in muscle prevents it. The compound's value is entirely in its support role: free testosterone amplification, mild estrogen control, and androgenic tone maintenance.
Who It Is For
Mesterolone's profile suits users who need an oral androgenic adjunct without adding hepatotoxic load — either because their cycle already includes another oral AAS, or because they specifically need the SHBG-displacement or libido effects that mesterolone provides reliably and without the systemic cost of a standard anabolic oral.
It is most appropriate for:
- On-cycle SHBG management — users on testosterone-based cycles where SHBG is elevated (naturally high responders, or those on long cycles where SHBG rises over time) benefit from mesterolone's displacement effect. Adding 50 mg/day to a 500 mg/wk testosterone cycle meaningfully increases free testosterone without requiring a dose increase in the injectable.
- TRT adjunct — men on testosterone replacement therapy who experience suboptimal libido or sexual function despite total testosterone being in range. Mesterolone at 25 mg/day addresses SHBG-bound testosterone, often resolving symptoms without changing the testosterone dose. The non-hepatotoxic profile allows indefinite use in this context.
- PCT libido bridge — during post-cycle therapy, SERM-driven estrogen suppression combined with low endogenous testosterone frequently produces low libido and sexual dysfunction. Mesterolone at 25–50 mg/day during PCT maintains androgenic tone and libido while SERMs restart the HPG axis. At these doses and this duration, mesterolone's mild HPG suppression does not meaningfully interfere with SERM-driven LH/FSH recovery.
Choose something else when: genuine aromatase inhibition is needed — mesterolone's anti-estrogen contribution is too weak to manage E2 on cycles with significant aromatization; use Anastrozole Tablets BD instead. When injectable DHT with a hardening and density effect is the goal, Mastabol 100 BD (drostanolone propionate) provides stronger androgenic and visual contribution. Mesterolone's specific value is the oral, non-hepatotoxic, libido-and-free-testosterone support role that neither of those alternatives covers.
Mesterolone vs Alternatives
| Compound | Key Differences | Choose Mesterolone When | Choose Alternative When |
|---|---|---|---|
| Mesterolone Tablets British Dragon |
Oral; non-17α-alkylated; no liver toxicity; SHBG binder; mild AI; strong androgenic libido effect; weak anabolic; ~12h half-life; daily oral dosing | Oral adjunct without hepatotoxic load; SHBG displacement + free T on any cycle; libido support during PCT or TRT; non-hepatotoxic oral stack partner | — |
| Anastrozole Tablets British Dragon |
Genuine aromatase inhibitor; suppresses E2 by up to ~85%; no androgenic activity; no SHBG effect; specifically targets estrogen production; required for meaningful on-cycle estrogen control | Dedicated estrogen management on an aromatizing cycle; elevated E2 confirmed by bloodwork; cycle requires genuine AI control | E2 is in range and only SHBG displacement + libido support is needed; oral androgenic adjunct wanted → Mesterolone |
| Mastabol 100 British Dragon |
Drostanolone propionate; injectable; strong androgen; not broken down by 3α-HSD in muscle → meaningful anabolic + hardening effect; SHBG binding also present; EOD injections; cosmetic pre-contest effect requires low body fat | Visual hardening and density effect alongside SHBG displacement; injectable format acceptable; pre-contest lean phase | Oral-only preference; injectable not practical; only libido + free T support needed without hardening goal → Mesterolone |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Free testosterone amplification on testosterone cycle | Testabol Enanthate (400–500 mg/wk) + Mesterolone (50–75 mg/day throughout) | Mesterolone displaces testosterone from SHBG, increasing the bioavailable fraction from the same testosterone dose. Users with naturally high SHBG or those whose SHBG rises over a long cycle see a measurable free testosterone benefit. No additional injectable required, no hepatotoxic oral added — Mesterolone's non-alkylated profile makes it a clean daily addition at zero liver cost. |
| Oral-primary stack with no additional liver burden | Testabol Propionate (300–400 mg/wk) + Stanabol Tablets BD (50 mg/day) + Mesterolone (50 mg/day) | Stanozolol is hepatotoxic (17α-alkylated); Mesterolone adds its SHBG displacement and androgenic drive alongside the winstrol without stacking another alkylated oral. The combination produces dryness from stanozolol + androgenic tone and libido support from mesterolone — two oral roles, one liver cost. |
| PCT libido bridge | Mesterolone (25–50 mg/day) alongside Clomiphene Tablets BD + Tamoxifen Tablets BD for weeks 1–4 of PCT | SERMs drive LH/FSH recovery but temporarily suppress estrogen, and low endogenous testosterone during early PCT creates a low-androgen environment that frequently causes libido and sexual function issues. Mesterolone at 25–50 mg/day maintains androgenic tone and libido during this window without interfering with SERM-driven LH/FSH stimulation at these doses. |
Side Effects & Management
Mesterolone's side effect profile is among the most manageable of any oral AAS — the absence of 17α-alkylation removes hepatotoxicity from the list entirely, and the absence of aromatization eliminates estrogenic concerns. Remaining risks are androgenic and, at higher doses, related to prostate androgen sensitivity.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Androgenic effects (acne, hair loss) | Mesterolone is a DHT derivative and a potent androgen in skin and sebaceous tissue. Sebaceous gland stimulation and acceleration of androgenetic alopecia in predisposed users occurs, particularly at 75–100 mg/day. As with other DHT-class compounds, finasteride does not apply — the compound is already a 5α-reduced metabolite and does not undergo further reduction. | Cystic acne: Isotroin (isotretinoin). Hair loss in predisposed users is a structural property of the DHT-derivative class — dose reduction is the only available mitigation. At 25 mg/day, androgenic side effects are generally mild even in predisposed users. |
| Prostate androgen stimulation | Mesterolone's direct DHT-like activity in prostate tissue means it stimulates prostate androgen receptors more than testosterone does. Users with benign prostatic hyperplasia (BPH) or a family history of prostate conditions should exercise particular caution. This is less relevant at 25 mg/day but becomes clinically meaningful at 75–100 mg/day in older users. | PSA and prostate evaluation at baseline for users over 40 or with prostate history. Monitor urinary symptoms (frequency, urgency, stream strength). Any worsening warrants dose reduction or discontinuation. |
| Lipid impact — mild HDL suppression | Non-aromatizing androgens suppress HDL to varying degrees. Mesterolone's lipid impact is less severe than injectable DHT-class compounds or oral 17α-alkylated AAS but is not zero. At standard doses, LDL elevation is minor. | Lipid panel at baseline and mid-use for extended runs. Elevated LDL: Atorlip (atorvastatin). Blood pressure monitoring: Amlip (amlodipine) if elevated above 135/85 mmHg. Lipid impact at 25–50 mg/day is modest enough that many users do not require pharmacological intervention. |
| HPG suppression (dose-dependent) | At 25 mg/day, mesterolone's suppression of LH and FSH is mild and partial — endogenous testosterone production is reduced but not fully shut down in most users. At 75–100 mg/day, suppression is more significant. This dose-dependence matters for users considering mesterolone during PCT or TRT, where the suppression profile at their specific dose determines compatibility with recovery. | At 25–50 mg/day during PCT alongside SERMs: suppression is generally mild enough not to interfere with SERM-driven LH/FSH recovery — but confirm by bloodwork post-PCT. At 75–100 mg/day as a standalone cycle: full PCT protocol applies on discontinuation. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Free testosterone + SHBG | Baseline; 4–6 weeks into use | Confirms mesterolone's primary pharmacological effect is working. If free testosterone has not increased meaningfully despite total testosterone being in range, SHBG displacement is the expected mechanism — a post-mesterolone free T check validates the clinical rationale for using it. |
| Lipid panel (HDL / LDL) | Baseline; at 8 weeks for extended runs; post-use | HDL above 35 mg/dL; LDL below 130 mg/dL. Mesterolone's lipid impact is milder than most AAS at standard doses. Add Atorlip only if LDL exceeds threshold on mid-run check. |
| PSA (prostate-specific antigen) | Baseline for users over 40 or with prostate history; at 12 weeks for extended use | Confirm no significant PSA rise from DHT-derived androgen stimulation. A doubling of PSA from baseline warrants dose review and urological evaluation. |
| LH + FSH | Baseline; end of use (or end of PCT if used during PCT) | Assess HPG suppression level at the dose used. At 25–50 mg/day alongside SERMs in PCT: expect partial suppression that should not prevent full SERM-driven recovery. Confirm LH/FSH are normalized at 3–4 weeks post-PCT. |
| Blood pressure | Target below 130/80 mmHg. Mesterolone's direct BP impact is modest; monitoring frequency can be lower than on potent injectable AAS cycles. |
PCT — Post-Cycle Therapy
Mesterolone's PCT requirements depend on dose and context. At 25–50 mg/day as an adjunct to a primary AAS cycle, PCT is driven by the primary cycle compounds — mesterolone's contribution to suppression is minor relative to the injectables or other orals in the stack. At 75–100 mg/day as a standalone or primary compound, structured PCT applies.
Using mesterolone during PCT: at 25–50 mg/day alongside Clomiphene and Tamoxifen, mesterolone is used by many as a libido bridge — maintaining androgenic tone and sexual function during the low-testosterone early weeks of PCT. At this dose, it does not meaningfully suppress LH/FSH stimulation driven by the SERMs. Discontinue mesterolone when PCT SERMs are completed; by that point, endogenous testosterone production should have recovered sufficiently that androgenic support is no longer needed.
| Product | Role |
|---|---|
| Clomiphene Tablets BD | 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4. Primary LH/FSH stimulant. Timing set by the longest-ester compound in the cycle — not by mesterolone, which clears within 2–3 days of the last dose. |
| Tamoxifen Tablets BD | 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4. Restores hypothalamic GnRH pulsatility. Run alongside Clomiphene for full 4-week PCT coverage. |
Practical Summary
- The only practical oral AAS with no hepatotoxic risk: this is mesterolone's single most clinically important property. It can be added to any cycle that already includes a hepatotoxic oral without contributing further liver burden — and can be run for extended periods that would be contraindicated with any 17α-alkylated compound.
- Split the dose 2–3× daily: the ~12-hour half-life means a once-daily dose creates pronounced troughs. Morning and evening dosing (or morning/midday/evening at higher doses) maintains more consistent blood levels throughout the day.
- It is a support compound, not a primary anabolic: 3α-HSD inactivation in muscle means mesterolone will not build muscle at any practical dose. Cycle planning should always designate it as an adjunct alongside a primary anabolic — it augments what is already there rather than building independently.
- SHBG testing validates the clinical rationale: if SHBG is not elevated at baseline, mesterolone's free testosterone contribution will be smaller than in a high-SHBG user. A pre-use SHBG and free testosterone check helps determine whether the compound is the right intervention or whether another approach would serve better.
- Prostate awareness above 50 mg/day: DHT-class androgens stimulate prostate tissue directly. Users over 40 or with any prostate history should have a PSA baseline before starting and monitor during extended use. This is not a reason to avoid the compound but a reason to monitor.
- PCT context: discontinue when SERMs end, not before: using mesterolone as a libido bridge through PCT is rational and widely practiced. Continue it through the full PCT window, then stop alongside the SERMs — endogenous testosterone recovery should cover androgenic support from that point.
Mesterolone stands apart from every other oral AAS in the British Dragon catalog by its unique structural profile — the only non-hepatotoxic oral androgen in practical performance use. Steroid Warehouse carries Mesterolone Tablets for users who need SHBG management, free testosterone amplification, or reliable libido support without the liver burden that comes with every other oral AAS option.
References
| Source | Description | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic-androgenic steroid pharmacology; covers androgen receptor binding, steroid metabolism, structure-activity relationships, ester pharmacokinetics, anabolic and androgenic mechanisms, detection methods, and adverse effects associated with AAS use | Kicman AT (2008) ↗ |
What is Mesterolone?
Mesterolone is an oral anabolic steroid for androgen support and estrogen control; see What is Mesterolone. It's effective—consult professionals for safe use.
What does Mesterolone do?
It enhances androgen levels, libido, and muscle hardness; see What Does Mesterolone Do. It reduces estrogen effects—monitor with labs.
How long does Mesterolone stay in your system?
Detectable for ~5-6 weeks; see How Long Does Mesterolone Stay in Your System. Monitor with professional guidance.
How do I take Mesterolone?
25-100 mg/day, split into 1-2 doses; see How to Take Mesterolone. Start at 25 mg—consult professionals for dosing.
How to cycle Mesterolone?
8-12 weeks, 25-50 mg/day, align PCT with main steroid; see How to Cycle Mesterolone. Stack with testosterone—consult professionals.
How long does it take to notice effects from Mesterolone?
Users often report gradual changes in well-being, physique appearance, and performance-related characteristics within the first few weeks of use.
What are the main benefits of Mesterolone?
Commonly discussed benefits include support for androgenic activity, improved muscle hardness, enhanced physique appearance, and assistance with hormonal balance.
Is Mesterolone used for bulking or cutting?
Mesterolone is most commonly associated with cutting and recomposition phases due to its reputation for supporting a lean, hard, and defined physique without significant water retention.
Related Products
